米托蒽醌联合亚甲蓝作为新一代乳腺癌前哨淋巴结示踪剂临床研究

Clinical Study of Mitoxantrone Combined with Methylene Blue as a New Sentinel Lymph Node Tracer for Breast Cancer

摘要: 背景：前哨淋巴结活检技术已经成为乳腺癌的常规治疗手段，应用最广的蓝染料法及现有的核素法均存在一定弊端。本研究旨在比较米托蒽醌联合核素的检出能力是否优于现有的两种双示踪法。方法：167例早期乳腺癌患者行双示踪法前哨淋巴结活检，分别记录统计检出状况。结果：80例亚甲蓝联合吲哚菁绿的患者平均检出数量3.33 ± 1.26，39例米托蒽醌联合核素为3.74 ± 1.37，46例亚甲蓝联合核素为3.00 ± 1.27，且差异有统计学意义。其中米托蒽醌的整体检出率87.67%，核素的检出率为72.18%，吲哚菁绿的检出率为78.20%，亚甲蓝的检出率为71.11%。并且过程中均无不良事件发生。结论：证明了米托蒽醌单一示踪和米托蒽醌联合核素检出能力的优越性。

Abstract: Background: Sentinel lymph node biopsy has become a routine treatment for breast cancer, but the most widely-used methylene blue and the existing nuclide method have some drawbacks. The purpose of this study was to compare the detection ability of mitoxantrone combined nuclide over the other two dual-tracer methods. Methods: 167 patients with early breast cancer underwent sentinel lymph node biopsy with double tracer. Results: The average detected quantity of 80 patients with methylene blue combined with indocyanine green was 3.33 ± 1.26, 39 patients with mitoxantrone combined with nuclide was 3.74 ± 1.37, 46 patients with methylene blue combined nuclide was 3.00 ± 1.27, and the difference was statistically significant. The overall detection rate of mitoxantrone, nuclide, indocyanine green and methylene blue was 87.67%, 72.18%, 78.20% and 71.11%, respectively. No adverse events occurred during the process. Conclusion: The superiority of mitoxantrone single tracer or mitoxantrone combined with nuclide detection is proved.